SEC Filing Analysis: Xenon Pharmaceuticals Inc. (XENE)

Executive Summary

• Trading Significance: Medium
• Key Takeaway: The Chief Financial Officer, Kelly Thomas Patrick, received a significant equity grant of 225,000 stock options and 30,000 Restricted Share Units (RSUs), signaling a strong long-term incentive plan.
• Market Impact: The grant represents a potential future dilution of 0.33% of total shares outstanding, which is a significant award for a key executive.

Company Information

Field	Value
Company	Xenon Pharmaceuticals Inc.
Ticker Symbol	XENE
CIK	0001582313
Industry	Pharmaceutical Preparations

Insider Information

Field	Value
Name	Kelly Thomas Patrick
CIK	0001410514
Title/Position	Chief Financial Officer
Relationship	Officer

Transaction Details

This filing reports two separate derivative grants. The primary transaction is detailed below, with both summarized in the analysis.

Field	Value
Form Type	4
Transaction Date	2025-10-15
Transaction Code	A (Award)
Security Type	Share Option (Right to Buy)
Shares Involved	225,000
Price Per Share	$0.00
Total Value	$0.00
Shares Owned After	225,000 (of this derivative)
Ownership Type	Direct

Financial Impact Assessment

Transaction Materiality

Note: Calculations are based on the combined 255,000 underlying shares from both the option and RSU grants.

Metric	Value
Transaction Value	$0 (Grant Price)
% of Market Cap	0.00%
Shares Transacted	255,000 (underlying shares)
% of Shares Outstanding	0.33%
Post-Transaction Ownership	255,000 (derivative securities)
Materiality Assessment	Significant (based on % of shares outstanding)

Impact Evaluation

• Market Cap Context: For Xenon, a company with a $3.21 billion market cap, this executive grant is a standard but substantial form of compensation. The value is not in the transaction itself, but in the future potential.
• Ownership Concentration: This grant establishes a new derivative position for the CFO, aligning his financial interests directly with the company's long-term stock performance.
• Dilution Impact: The 255,000 shares underlying the grants represent a potential dilution of 0.33% to existing shareholders. While not immediate, this is a notable level for a single executive grant and falls into the 'Significant' category based on our 0.25%-0.5% threshold.
• Transaction Significance: The significance is medium. While no capital was exchanged, the size of the potential stake awarded to a C-level executive is a key indicator of the board's confidence and desire to retain top talent.

Market Impact Analysis

Stock Impact Prediction

• Direction: Neutral to slightly Bullish
• Reasoning: Equity grants are a common practice and not a direct market transaction. However, a large grant to a key financial officer can be viewed positively as it ensures long-term alignment with shareholder value creation.

Volume & Sentiment

• Expected Volume Impact: Minimal. As this is not an open market transaction, it will not directly impact trading volume.
• Sentiment Indicator: Bullish. The grant incentivizes the CFO to drive performance, which is a positive signal for investors.

Investment Insights

Positive Market Indicators

• Strong incentive for a key executive (CFO) to increase shareholder value.
• Long-term alignment of interests between management and shareholders.

Risk Factors

• Potential for 0.33% shareholder dilution over the vesting period.
• The value of the compensation is tied to future stock performance, which is not guaranteed.

Key Takeaways

1. Xenon's CFO received a significant equity package totaling 255,000 potential shares.
2. The grant represents 0.33% of the company's total shares outstanding, making it a significant award.
3. The transaction is a long-term incentive, not an open-market buy, aligning the CFO's success with the company's stock price.

Additional Context

Transaction Notes

• Vesting Schedule (Options): 25% vest on the first anniversary (Oct 2026), with the remaining 75% vesting monthly over the following 3 years.
• Vesting Schedule (RSUs): 25% vest on each of the first four anniversaries of the grant date, starting Oct 2026.
• Option Details: The 225,000 options have an exercise price of $41.90 and expire in October 2035.